Target intelligence / Profile preview

Corneal stroma extracellular matrix proteins (primarily collagen fibers)

Molecular classification
Extracellular matrix protein, Structural protein, Collagen (type I, III, V, VI, XII, XIV), Proteoglycan (decorin, lumican, keratocan, mimecan, biglycan, fibromodulin)
01

Overview

The corneal stroma is composed primarily of a highly organized lattice of collagen fibers (mainly type I and V, with contributions from types III, VI, XII, and XIV), which are interwoven with a variety of proteoglycans (decorin, lumican, keratocan, mimecan, biglycan, fibromodulin). This unique arrangement is essential for the transparency, shape, and mechanical properties of the cornea. The proper spacing and diameter of collagen fibrils, regulated by proteoglycans and minor collagens, are critical for minimizing light scatter and maintaining optical clarity. The stroma matrix is not a single molecule or molecular target, but rather a complex anatomical and physiological structure whose components play both structural and regulatory roles in corneal health and disease. This entry describes a category of structural proteins, not a single canonical therapeutic target or receptor, so it is best understood as a collection of proteins critical for tissue architecture and function, rather than a druggable pharmacological target.

Other names
Corneal collagen fibersCorneal stromal ECM proteinsCorneal collagen matrixCorneal stromal matrix proteins
02

Mechanism of action

No unified mechanism as no single drug targets the entire ECM. Collagen cross-linking (photochemical induction of additional bonds in collagen matrix). Enzymatic digestion/modification in experimental settings

03

Biological functions

Maintenance of corneal transparencyMechanical strength and shape of corneaRegulation of collagen fibril spacing and organizationRegulation of hydrationSupport for stromal keratocytesOptical focusing (by maintaining corneal form and optical properties)
04

Disease associations

Corneal dystrophies (e.g. cornea plana, keratoconus)Corneal scarring/opacitiesConnective tissue diseases affecting collagensWound healing/fibrosis
05

Safety considerations

Manipulation of the stroma carries risk of corneal opacification, loss of transparency, scarring, and biomechanical weakening.
06

Interacting drugs

None directly; no approved drugs directly target the overall corneal stroma ECM as a molecular entity
07

Biomarkers

Altered collagen composition or proteoglycan levels (experimental and diagnostic corneal imaging)Mutations in specific ECM genes (e.g., KERA for keratocan, LUM for lumican) in corneal dystrophies

Beyond the preview

Go deeper on Corneal stroma extracellular matrix proteins (primarily collagen fibers).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Corneal stroma extracellular matrix proteins (primarily collagen fibers).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call